Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
TAGAMET (cimetidine) is an oral H2-receptor antagonist approved in 1977 for treating acid-related gastrointestinal disorders. It reduces gastric acid secretion and is used for peptic ulcer disease, gastroesophageal reflux, and related conditions. As a small molecule, it represents an older generation of acid-suppression therapy now largely superseded by proton pump inhibitors.
As LOE approaches, the TAGAMET brand team is likely focused on lifecycle extension, generic transition management, and protecting remaining market share in a contracted portfolio.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on TAGAMET offers limited career advancement in a shrinking, post-LOE portfolio. Roles are primarily defensive and operational rather than strategic, making this assignment useful for supply-chain and compliance expertise but not for commercial brand-building experience.
Worked on TAGAMET at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.